

**Amendments to the Claims:**

Please amend claim 1, as shown in the listing of claims that follows. This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently amended) A method for treating toxicity due to a pyrimidine nucleoside analog in an animal comprising administering to said animal a pharmaceutically effective amount of an acylated derivative of uridine or cytidine selected from the group consisting of triacetyluridine and ethoxycarbonyluridine or triacetylcytidine,

wherein said pyrimidine nucleoside analog is selected from the group consisting of 5-fluorouracil (5-FU), Tegafur, 5-fluoroorotate, 5'-deoxy-5-fluorouridine, 5-fluorouridine, 2'-deoxy-5-fluorouridine, fluorocytosine, trifluoromethyl-2'-deoxyuridine, arabinosyl cytosine, cyclocytidine, 5-aza-2'-deoxycytidine, arabinosyl 5-azacytosine, 6-azacytidine, N-phosphonoacetyl-L-aspartic acid (PALA), pyrazofurin, 6-azauridine, azaribine, thymidine, 3-deazauridine, AZT, dideoxycytidine, 5-ethyl-2'-deoxyuridine, 5-iodo-2'-deoxyuridine, 5-bromo-2'-deoxyuridine, 5-methylamino-2'-deoxyuridine, arabinosyluracil, dideoxyuridine and (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine;

and wherein said toxicity is selected from the group consisting of damage to hematopoietic tissue and damage to mucosal tissues.

2. (Canceled)

3. (Original) A method as in claim 1 wherein said toxicity is damage to hematopoietic tissue.

4. (Original) A method as in claim 1 wherein said toxicity is damage to mucosal tissues.

Claims 5-17 (Canceled).

18. (Previously presented) A method as in claim 1 wherein said administering step also includes administering an inhibitor of uridine phosphorylase selected from the group consisting of benzylacyclouridine, benzyloxybenzylaceto-uridine, aminomethyl-benzylacyclouridine, aminomethyl-benzyloxybenzylaceto-uridine, hydroxymethyl-benzylacyclouridine, hydroxymethyl-benzyloxybenzylacyclouridine, 2,2'-anhydro-5-ethyluridine, 5-benzyl barbiturate, 5-benzyloxybenzyl barbiturate, 5-benzyloxybenzyl-1-[(1-hydroxy-2-ethoxy)methyl] barbiturate, 5-benzyloxybenzylacetyl-1-[(1-hydroxy-2-ethoxy)methyl] barbiturate, and 5-methoxybenzylacetylacetylbarbiturate.

19. (Canceled)

20. (Currently amended) A method as in claim 1 wherein said acylated derivative is triacetylcytidine, and said administering step also includes administering an inhibitor of cytidine deaminase selected from the group consisting of tetrahydrouridine and tetrahydro-2'-deoxyuridine.

21. (Canceled)

22. (Previously presented) A method as in claim 1 wherein said administering step also includes administering an inhibitor of nucleoside transport selected from the group consisting of dipyridamole, probenecid, lidoflazine and nitrobenzylthioinosine.

23. (Canceled)

24. (Previously presented) A method as in claim 1 wherein said administering step also includes administering an agent which enhances hematopoiesis selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, granulocyte colony stimulating factor, granulocyte/macrophage colony stimulating factor, stem cell factor, erythropoietin, glucan, and polyinosine-polycytidine.

25. (Previously presented) A method as in claim 1 wherein said administering step also includes administering a compound capable of enhancing the uptake and phosphorylation of nucleosides into cells selected from the group consisting of insulin and insulinogenic carbohydrate.

26. (Previously presented) A method as in claim 1, wherein said acylated derivative of uridine is triacetyluridine.

27. (Previously presented) A method as in claim 26, wherein said pyrimidine nucleoside analog is 5-fluorouracil (5-FU).

28. (Previously presented) A method as in claim 26, wherein said pyrimidine nucleoside analog is AZT and said toxicity is damage to hematopoietic tissue.